16:43 , Jul 20, 2018 |  BC Week In Review  |  Financial News

RNAi company OliX lists in Korea

OliX Pharmaceuticals Inc. (KOSDAQ:226950) raised KrW43.2 billion ($38.3 million) on July 18 through the sale of 1.2 million shares at KrW36,000 in an IPO underwritten by NH Investment & Securities. Next half, OliX expects to complete...
23:02 , Jul 17, 2018 |  BC Extra  |  Financial News

RNAi company OliX lists in Korea

OliX Pharmaceuticals Inc. (KOSDAQ:226950) raised KrW43.2 billion ($38.3 million) through the sale of 1.2 million shares at KrW36,000 in an IPO on KRX underwritten by NH Investment & Securities. Next half, OliX expects to complete a...
16:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

FibroGen's pamrevlumab improves survival in Phase I/II for pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported additional data from 37 treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel significantly increased median...
22:40 , Jun 5, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; imaging

TECHNOLOGY: Diagnostic assays; fluorescence A nanoparticle- and fluorophore-based method for detecting hypertrophic scar fibroblasts could non-invasively diagnose hypertrophic scarring. The method, dubbed NanoFlare, utilizes a double-stranded oligonucleotide: the first strand is complementary to a sequence...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

FibroGen reports Phase I/II data for pamrevlumab in pancreatic cancer

FibroGen Inc. (NASDAQ:FGEN) reported data from 37 evaluable treatment-naïve patients with locally advanced, unresectable pancreatic cancer in an open-label, U.S. Phase I/II trial showing that pamrevlumab (FG-3019) plus gemcitabine and Abraxane nab-paclitaxel improved the proportion...
18:00 , Aug 24, 2017 |  BC Innovations  |  Emerging Company Profile

Heartfelt WISPER

HaYa Therapeutics is using antisense oligonucleotides to target the lncRNA WISPER to treat cardiac fibrosis caused by cardiovascular diseases such as myocardial infarction. Because WISPER expression is confined to the heart, the newco is betting...
20:41 , Aug 18, 2017 |  BioCentury  |  Finance

IPF call options

Surprise readouts from two programs in idiopathic pulmonary fibrosis have generated over $1.4 billion in market value, and there could still be plenty of upside ahead. After market close on Aug. 7, FibroGen Inc. (NASDAQ:FGEN) reported...
16:29 , Aug 18, 2017 |  BC Week In Review  |  Financial News

FibroGen raises $326M in follow-on

FibroGen Inc. (NASDAQ:FGEN) raised $326 million through the sale of 8 million shares at $40.75 in a follow-on underwritten by Goldman Sachs, Citigroup and Leerink on Aug. 15. Earlier this month, FibroGen’s pamrevlumab (FG-3019) met the...
20:14 , Aug 16, 2017 |  BC Extra  |  Financial News

FibroGen raises $326 million in follow-on

FibroGen Inc. (NASDAQ:FGEN) raised $326 million through the sale of 8 million shares at $40.75 in a follow-on underwritten by Goldman Sachs, Citigroup and Leerink. The price is a 7% discount to FibroGen's closing price...
23:00 , Aug 10, 2017 |  BC Week In Review  |  Clinical News

FibroGen's pamrevlumab meets in Phase II for IPF

FibroGen Inc. (NASDAQ:FGEN) reported top-line data from a Phase II trial in 103 patients with idiopathic pulmonary fibrosis (IPF) showing that pamrevlumab (FG-3019) as monotherapy met the primary endpoint of improving forced vital capacity...